Ergomed plc Notice of Results (8501N)

TIDMERGO

RNS Number : 8501N

Ergomed plc

14 August 2017

PRESS RELEASE

FOR IMMEDIATE RELEASE

Notice of interim results

London, UK - 14 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, will announce its Interim Results for the six months ended 30 June 2017 on Monday 18 September 2017.

Dr Dan Weng, Chief Executive Officer, and Stephen Stamp, Chief Financial Officer, will host a presentation and conference call for analysts at 9:00am BST on the day of the results at the offices of Numis Securities, The London Stock Exchange Building, 10 Paternoster Square, London, EC4M 7LT.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 
                                                        1483 503205 
 Dan Weng (Chief Executive Officer) 
 Stephen Stamp (Chief Financial 
  Officer) 
 
 Numis Securities Limited                              Tel: +44 (0) 
                                                       20 7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black (Joint Broker) 
 
 N+1 Singer                                            Tel: +44 (0) 
                                                       20 7496 3000 
 Alex Price (Joint Broker) 
 
 Consilium Strategic Communications                    Tel: +44 (0) 
  - for UK enquiries                                   20 3709 5700 
 Chris Gardner / Mary-Jane              [e-mail] 
  Elliott 
  Ivar Milligan / Philippa Gardner 
 
 MC Services - for Continental                         Tel: +49 211 
  European enquiries                                      5292 5222 
 Anne Hennecke 
 
 

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORGGUCCRUPMPUW

(END) Dow Jones Newswires

August 14, 2017 02:00 ET (06:00 GMT)